The Consumer Staples Select Sector SPDR Fund (XLP)
- Previous Close
80.16 - Open
80.51 - Bid 81.45 x 1800
- Ask 82.11 x 900
- Day's Range
80.39 - 82.25 - 52 Week Range
73.56 - 84.53 - Volume
13,649,419 - Avg. Volume
14,877,022 - Net Assets 16.75B
- NAV 80.15
- PE Ratio (TTM) 22.86
- Yield 2.50%
- YTD Daily Total Return 2.51%
- Beta (5Y Monthly) 0.56
- Expense Ratio (net) 0.08%
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
SPDR State Street Global Advisors
Fund Family
Consumer Defensive
Fund Category
16.75B
Net Assets
1998-12-16
Inception Date
Performance Overview: XLP
View MoreTrailing returns as of 4/16/2025. Category is Consumer Defensive.
People Also Watch
Holdings: XLP
View MoreTop 10 Holdings (61.05% of Total Assets)
Sector Weightings
Recent News: XLP
View More
Research Reports: XLP
View MoreBiogen Earnings: Guidance Slightly Disappointing, Fair Value Lowered on Reassessment of Leqembi
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetLowering to HOLD as EPS is expected to decline in 2025
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in multiple sclerosis drugs and launched the first approved treatments for spinal muscular atrophy and Alzheimer's disease. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,605 people, and is a component of the S&P 500.
RatingPrice TargetBiogen Earnings: Guidance Slightly Disappointing, Fair Value Lowered on Reassessment of Leqembi
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetMid Cap U.S. Pick List February 2025
This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.